Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qianglidingxuan Tablets for Mild to Moderate Essential Hypertension
NCT05521282Phase 4Completed
- Sponsor
- Guang'anmen Hospital
- Start
- Mar 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Qianglidingxuan in essential hypertension, sponsored by Guang'anmen Hospital. Started Mar 2021; status: completed.
02
Drugs
Qianglidingxuan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT05521282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521282.